| Fatigue in people with bowel conditions | Fatigue decreased by 8.1 points with B12 and 8.3 points with placebo on the CIS subjective fatigue subscale. B12 provided no additional reduction in fatigue. | 2/4 LowOne study with 95 participants. The available description provides insufficient detail to fully verify allocation concealment or how the reported results were selected. The assessment applies to fatigue in this group and cannot be generalized to all causes of fatigue. | 11 studySurplus vitamin B12 use does not reduce fatigue in patients with Irritable Bowel Syndrome or inflammatory bowel disease: A randomized double-blind placebo-controlled trial ↗ | 95 adults aged 18–65 with marked fatigue and either irritable bowel syndrome or inflammatory bowel disease. Baseline B12 was ≥150 pmol/L. | - Surplus vitamin B12 use does not reduce fatigue in patients with Irritable Bowel Syndrome or inflammatory bowel disease: A randomized double-blind placebo-controlled trial ↗
|
|---|
| Memory in people aged 75 and older with moderately low B12 | On a word-list memory test, the B12 group scored an average of 1.4 words lower than the placebo group after adjustment for baseline scores. The 95% confidence interval ranged from −2.9 to +0.1 words. The study found no advantage for B12 over placebo in memory performance or on the other cognitive tests studied. | 2/4 LowOne study. Cognitive results were available for 184 of 201 participants. The interval for the estimate includes the possibility of no difference. The result applies to older adults without pronounced symptoms of deficiency. | 11 studyEffects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial ↗ | 201 people aged 75 and older with B12 levels of 107–<210 pmol/L at screening, without anemia or marked memory impairment. Cognitive data were available for 184 participants. | - Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial ↗
|
|---|
| Peak power in a short cycling sprint | The highest peak power recorded across five 30-second sprints was 764.1 W with B12 and 734.2 W with placebo, a difference of 29.9 W, or about 4.1% (p=0.016). The study did not assess endurance over longer efforts. | 2/4 LowThe study included only 18 men and three days of use per condition. It did not test whether the result would persist with longer-term training. Participants received both treatments in sequence. The seven-day break leaves open the possibility of a carryover effect between periods. | 11 studyShort-Term Methylcobalamin Supplementation Is Associated with Changes in Anaerobic and Cognitive Performance in Amateur Cyclists: A Randomized Crossover Trial ↗ | 18 male recreational cyclists aged 18–45 who were training. Each completed both study conditions. | - Short-Term Methylcobalamin Supplementation Is Associated with Changes in Anaerobic and Cognitive Performance in Amateur Cyclists: A Randomized Crossover Trial ↗
|
|---|
| Total blood B12 in people with low baseline levels | Mean B12 rose above 240 pmol/L in both groups. From day 30 through day 90, it was higher with 2,000 µg once a week than with 50 µg daily (p<0.01 for between-group comparisons at those time points). | 2/4 LowOne small study compared two active regimens, with no group that received zero B12. Of the 40 participants, 36 completed testing. A change in a blood marker alone cannot establish whether participants felt any different. | 11 studyEffect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗ | 40 vegans and vegetarians with B12 levels <220 pmol/L. Of these, 36 completed the study, 18 in each group. | - Effect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗
|
|---|
| Active B12 in the blood (holotranscobalamin) | Holotranscobalamin, the fraction of B12 bound to a transport protein, increased in both groups (p<0.0001 for change over time). The study found no convincing difference between the regimens. | 2/4 LowOne small study compared two active regimens, with no group that received zero B12. Of the 40 participants, 36 completed testing. A change in a blood marker alone cannot establish whether participants felt any different. | 11 studyEffect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗ | 40 vegans and vegetarians with B12 levels <220 pmol/L. Of these, 36 completed the study, 18 in each group. | - Effect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗
|
|---|
| Methylmalonic acid in people with low B12 | Methylmalonic acid, a marker that can rise when B12 is low, decreased in both groups (p<0.0001 for change over time). The study found no convincing difference between the regimens. | 2/4 LowOne small study compared two active regimens, with no group that received zero B12. Of the 40 participants, 36 completed testing. A change in a blood marker alone cannot establish whether participants felt any different. | 11 studyEffect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗ | 40 vegans and vegetarians with B12 levels <220 pmol/L. Of these, 36 completed the study, 18 in each group. | - Effect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗
|
|---|
| Homocysteine in people with low B12 | Blood homocysteine decreased in both groups (p<0.0001 for change over time). The study found no convincing difference between the regimens. This was a blood test result. The test was not used to assess how participants felt. | 2/4 LowOne small study compared two active regimens, with no group that received zero B12. Of the 40 participants, 36 completed testing. A change in a blood marker alone cannot establish whether participants felt any different. | 11 studyEffect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗ | 40 vegans and vegetarians with B12 levels <220 pmol/L. Of these, 36 completed the study, 18 in each group. | - Effect of two different sublingual dosages of vitamin B(12) on cobalamin nutritional status in vegans and vegetarians with a marginal deficiency: A randomized controlled trial ↗
|
|---|
| Pain associated with diabetic nerve damage in people taking metformin | On the painDETECT neuropathic pain questionnaire, scores fell from 18.4 to 17.1 points with B12 and rose from 19.3 to 20.9 with placebo. The changes were −1.3 and +1.6 points, respectively (adjusted between-group p<0.001). | 2/4 LowOne study with 90 participants. It measured many outcomes, and it is unclear whether their order of importance was specified in advance. The study did not report an exact confidence interval for the difference in changes. It is difficult to tell from the study how noticeable the change would be to an individual. | 11 studyVitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 90 people with type 2 diabetes and peripheral and autonomic nerve damage. They had taken metformin for ≥4 years and had B12 levels <400 pmol/L. | - Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Blood B12 with oral treatment and injections in people aged 65 and older | By week 8, B12 had reached ≥211 pg/mL in 133 of 140 participants taking oral B12 and 129 of 143 receiving injections. After a year, the figures were 103 of 140 (73.6%) and 115 of 143 (80.4%), respectively. Oral treatment met the prespecified noninferiority criterion at week 8. At one year, it failed to meet that criterion. | 2/4 LowIn the single open-label study, participants knew how they received B12. Of the 283 participants, 229 completed one year of follow-up. The 95% confidence interval for the difference in proportions at one year ranged from −16.6 to +2.9 percentage points. The study compared specific regimens, including infrequent oral dosing after week eight. | 11 studyOral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12) ↗ | 283 people aged 65 and older with B12 levels <211 pg/mL. Of these, 140 received oral B12 and 143 received injections. 229 completed the year of follow-up. | - Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12) ↗
|
|---|
| Methylmalonic acid in people with borderline B12 levels | After one month, methylmalonic acid was 0.23 µmol/L with B12 and 0.37 µmol/L with placebo. The difference adjusted for baseline was −0.13 µmol/L (95% confidence interval −0.19 to −0.06). Three months after treatment ended, the difference was no longer detectable. | 3/4 ModerateThe result concerns a specific blood test. Symptom relief was outside its scope. The study included 50 people, and blood test results at one month were available for 45. The decrease in the marker was confirmed. The study did not demonstrate that the effect persisted long term after discontinuation. | 11 studyOral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial ↗ | 50 adults aged 18–91 with B12 levels of 125–200 pmol/L at screening | - Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial ↗
|
|---|